US Patent

US12514899 — Methods of treatment using single doses of oritavancin

Method of Use · Assigned to Melinta Therapeutics LLC · Expires 2029-08-29 · 3y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent describes methods for treating bacterial infections in humans and animals using a single dose of oritavancin.

USPTO Abstract

Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.

Drugs covered by this patent

oritavancin-diphosphate (ORITAVANCIN DIPHOSPHATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4398`	—	oritavancin-diphosphate
`U-4398`	—	oritavancin-diphosphate

Patent Metadata

Patent number: US12514899
Jurisdiction: US
Classification: Method of Use
Expires: 2029-08-29
Drug substance claim: No
Drug product claim: No
Assignee: Melinta Therapeutics LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.